Study: Big Pharma To Blame Antibiotic-Resistant Bacteria In India
worrying study has suggested that it may pose a wider health risk
A new study conducted by British bacteriologists in India has revealed that the use of Big Pharma sponsored Antibiotic drugs in India has now made bacteria resistant to the drug.
The worrying study has suggested that it may pose a wider health risk if it spreads beyond the borders of the country.
The study alleges that the proliferation of non-approved antibiotics, usual olf by Bih Parma in India, has increased the growth of drug-resistant bacteria that could end up killing thousands of people.
Sputnik new reports: According to the reports: "Drug companies, some international and even US-based, are selling millions of dubious and unapproved cocktails of antibiotics in India, all of which could spur the development of drug-resistant bacteria and imperil patients. Drug companies should be required to justify the sale of products in India that do not have the approval of their own national regulators and, in multiple cases, not even the approval of the Indian regulator,"
The authors of the research paper, led by Patricia McGettigan of Queen Mary University of London, have advocated a widespread public awareness drive, backed by strong regulatory mechanisms as the only way out to effectively combat the threat. Dr. Bobby John, a founding member of Global Health Advocates, India supports the recommendations.
"There are two critical areas that need attention for addressing antibiotic resistance in India. There needs to be a strong prescription auditing mechanism to check the prescription against the indication for which the antibiotics were prescribed. This can close the loopholes for both bad clinical practices and over-the-counter sales. Second is the Strengthening of the Central Drugs Standard Control Organization Company (CDSCO) mechanism to do systematic and random product quality checks, to eliminate low quality and low quantity packages of antibiotics," Dr. Bobby John, who writes for Indian publications' health columns, told Sputnik.
Prof. McGettigan and her colleagues pulled antibiotic sales figures from a commercial database of Indian drug distribution called PharmaTrac. They looked at sales between October 2007 and November 2012. They then compared the inventory of drugs sold in India to the list of drugs approved by India's Central Drugs Standard Control Organization (CDSCO) as well as those approved by the US Food and Drug Administration (FDA) and the European Medical Agency (EMA), according to an analytical report on the study published by the portal arstechnica.com.
"The researchers found that drug companies sold 86 regular, so-called "single-dose antibiotics" and 118 "fixed-dose combination" antibiotics over the five-year period while drug companies sold just five of these in the US and UK during the same period," the report further adds.